A silent pandemic, bacterial resistance to antibiotics is killing increasingly more people around the world and jeopardizing decades of medical progress.
Tamrisa aims to provide a novel, comprehensive, ambitious and sustainable response to AMR threat, in line with WHO guidelines.
Tamrisa is currently working on the development of dabocins, a new class of antibacterials derived from the diazabicyclooctane scaffold. Dabocins present the unique ability to both inhibit Penicillin-Binding Proteins (PBP) and demonstrate outstanding stability to A, B, C and D β-lactamases.
Within this new class, the team is pursuing two active programs of novel chemical entities to treat carbapenem-resistant Gram-negative bacterial infections : EBL-1463 and 2G-DAB.
These programs benefit from the long-standing support of CARB-X, Novo Holdings REPAIR Impact Fund and Roche - several among the world most influential institutions in the AMR field.
| Project | Stage | Support |
|---|---|---|
| EBL-1463 (i.v.)Carbapenem-resistant Enterobacterales | Lead op.PreclinicalPhase 1 |  |
| 2G-DAB (i.v.)Carbapenem-resistant EnterobacteralesCarbapenem-resistant PseudomonasCarbapenem-resistant Acinetobacter | Lead op.PreclinicalPhase 1 |  |
Equipped with strong in-house chemistry and biology capabilities, the team has built over the years a unique know-how for the identification and development of meaningful anti-infective drugs leads.
Located right next to Paris, the team nurtures and collaborates with a broad network of AMR experts and partners around the globe.
Tamrisa is committed to promote and favor in all respects the use of the relevant antibiotic for the relevant patient at the relevant dose for the relevant duration, and thus contribute to limit resistance expansion to both existing and future molecules.
This is reflected at every level of the company operations, from the choice of R&D programmes, to collaboration with the authorities, to a responsible approach in bringing existing molecules to market.
This may also extend in the future into any action supporting this critical goal in the fight against AMR.
Tamrisa is committed to reinforce access for patients around the world of proven existing antibiotics – still most useful in the
pharmacopeia although no longer always available.
To date, Tamrisa has already built a portfolio of eight long proven valuable antibiotics, registered and commercialized in more than 40 countries through a network of distribution partners.
With the help of manufacturing partners, Tamrisa is committed to reinforce and secure overtime their respective supply chains.
Please note that registration may vary from country to country. Always refer to the locally approved product information.